Real‐World Experience With Oleogel‐S10 for Wounds in Epidermolysis Bullosa

Background Oleogel‐S10 is the first approved drug for the treatment of wounds in patients with junctional and dystrophic epidermolysis bullosa. Results from the clinical trials, early access programme and open‐label study are available, showing good safety and tolerability and a positive effect on the overall wound surface. Objectives In this single‐center retrospective study we evaluated the use of Oleogel‐S10 in routine wound care in patients with different epidermolysis bullosa subtypes. Methods Sixteen patients with epidermolysis bullosa whom Oleogel‐S10 was prescribed post‐market authorization between September 2022 and September 2023 were included. Chronic wounds were chosen for follow‐up and assessment, and considered as target wounds. Patients used Oleogel‐S10 as labeled. Wounds, pain, and itch were assessed, and patients were asked how they felt about the treatment at each follow‐up visit. Results Eleven of 14 patients who used Oleogel‐S10 were satisfied with the treatment results concerning wound healing, pain, and itch, and used it on a regular basis. Both patients with junctional and dystrophic epidermolysis bullosa experienced such positive effects. Three patients with dystrophic epidermolysis bullosa discontinued the treatment because no benefit was felt. Conclusions In our experience, Oleogel‐S10 performed well regarding patient‐reported outcomes. It is part of the therapeutic arsenal of junctional and dystrophic epidermolysis bullosa‐associated wounds.